These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3141845)

  • 1. [Blood platelet changes in myeloproliferative disorders].
    D'Angelo G; Calvano D; Giardini C
    Minerva Med; 1988 Oct; 79(10):853-7. PubMed ID: 3141845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
    Wehmeier A; Südhoff T; Meierkord F
    Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S; Davis JL; Walsh PN; Gardner FH
    Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders.
    Emiliani C; Ciferri S; Mencarelli S; Mezzasoma AM; Momi S; Orlacchio A; Gresele P
    Platelets; 2006 Feb; 17(1):20-9. PubMed ID: 16308183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes.
    Finazzi G; Budde U; Michiels JJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():71-8. PubMed ID: 8951775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders.
    Pareti FI; Gugliotta L; Mannucci L; Guarini A; Mannucci PM
    Thromb Haemost; 1982 Apr; 47(2):84-9. PubMed ID: 7101243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased response to arachidonic acid and U-46619 and resistance to inhibitory prostaglandins in patients with chronic myeloproliferative disorders.
    Cortelazzo S; Galli M; Castagna D; Viero P; de Gaetano G; Barbui T
    Thromb Haemost; 1988 Feb; 59(1):73-6. PubMed ID: 3129810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal aggregation and increased size of platelets in myeloproliferative disorders.
    Cortelazzo S; Barbui T; Bassan R; Dini E
    Thromb Haemost; 1980 Jun; 43(2):127-30. PubMed ID: 7455970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet abnormalities in myeloproliferative disorders.
    Holme S; Murphy S
    Clin Lab Med; 1990 Dec; 10(4):873-88. PubMed ID: 2272179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet adhesion.
    Packham MA; Mustard JF
    Prog Hemost Thromb; 1984; 7():211-88. PubMed ID: 6397767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood platelet calcium content and aggregation behaviour in myeloproliferative disorders and secondary thrombocytosis.
    Mindner K; Ostermann G; Hochhaus A; Höche D; Till U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):461-4. PubMed ID: 2465953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Shortening of acetylsalicylic acid-prolonged bleeding time by means of desmopressin].
    Beck KH; Bleckmann U; Mohr P; Kretschmer V; Huss B
    Beitr Infusionsther Transfusionsmed; 1994; 32():437-9. PubMed ID: 9480140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet membrane fatty acids in thrombocytosis due to myeloproliferative disorders.
    Leoncini G; Maresca M; Balestrero F; Benatti U; Armani U; Piana A
    Cell Biochem Funct; 1984 Jan; 2(1):23-5. PubMed ID: 6467512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders.
    Malpass TW; Savage B; Hanson SR; Slichter SJ; Harker LA
    J Lab Clin Med; 1984 Jun; 103(6):894-904. PubMed ID: 6233383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.
    Di Minno G; Cerbone AM; Mattioli PL; Turco S; Iovine C; Mancini M
    J Clin Invest; 1985 Feb; 75(2):328-38. PubMed ID: 3156146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet abnormalities in idiopathic myelofibrosis: functional, biochemical and immunomorphological correlations.
    Leoni P; Rupoli S; Lai G; Brunelli MA; Belmonte MM; Pugnaloni A; Rabini RA; Mazzanti L; Biagini G
    Haematologica; 1994; 79(1):29-39. PubMed ID: 15378946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathobiology of animal platelets.
    Meyers KM
    Adv Vet Sci Comp Med; 1985; 30():131-65. PubMed ID: 3004158
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder.
    Handa M; Watanabe K; Kawai Y; Kamata T; Koyama T; Nagai H; Ikeda Y
    Thromb Haemost; 1995 Mar; 73(3):521-8. PubMed ID: 7667837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.